bioAffinity (BIAF) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$5.9M

Revenue (quarter)

$1.5M

Revenue growth (year over year)

+18.99%

Gross profit (trailing twelve months)

$2.0M

Gross margin

34.61%

Net income (trailing twelve months)

−$15.2M

Net income (quarter)

−$3.4M

Net income growth (year over year)

+17.11%

Net margin

−257.33%

Return on equity

−1860.15%

EPS (trailing twelve months)

−$20.25

Book value per share

$8.33

P/E (trailing twelve months)

—

Price to book

1.22

Debt to assets

50.54%

Payout ratio

—

Dividend yield

—

Company profile

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

• Is bioAffinity (BIAF) profitable?

  No. bioAffinity reported a net loss of $15.2M over the trailing twelve months.

• How much revenue does bioAffinity (BIAF) make?

  bioAffinity generated $5.9M in revenue over the trailing twelve months, up 18.99% year over year.

• How do I buy stock in bioAffinity (BIAF)?

  BIAF trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.